Expression genomics and cancer drug development

Drug Development Research

Volumn 62, Issue 4, 2004, Pages 295-302

  Liu, Edison T ^a  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

Cancer drugs; Genomics; Microarrays; Tag libraries

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; DOXORUBICIN; FLUOROURACIL; HYDROGEN PEROXIDE; LIOTHYRONINE; MENADIONE; PROTEIN TYROSINE KINASE; TERT BUTYL HYDROPEROXIDE;

BREAST CANCER; CHROMATIN; DNA MICROARRAY; DNA SEQUENCE; DRUG EXPOSURE; DRUG RESEARCH; DRUG TARGETING; GENE CONTROL; GENE EXPRESSION PROFILING; GENE LIBRARY; GENETIC TRANSCRIPTION; GENOMICS; HUMAN; IMMUNOPRECIPITATION; MOLECULAR CLONING; NONHUMAN; PROGNOSIS; RECEPTOR BLOCKING; REGULATORY MECHANISM; REVIEW; SERIAL ANALYSIS OF GENE EXPRESSION; TREATMENT OUTCOME;

EID: 11444260265     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10388     Document Type: Review

References (58)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511.
2. Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Aprelikova O, Pace AJ, Fang B, Koller BH, Liu ET. 2001. BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells. J Biol Chem 276:25647-25650.
3. Bani MR, Nicoletti MI, Alkharouf NW, Ghilardi C, Petersen D, Erba E, Sausville EA, Liu ET, Giavazzi R. 2004. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 3:111-121.
4. Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. 2004. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594-601.
5. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R, Dohner H, Pollack JR. 2004. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350:1605-1616.
6. Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D, Piccolboni A, et al. 2004. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 116:499-509.
7. Chandrasekharan S, Qiu TH, Alkharouf N, Brantley K, Mitchell JB, Liu ET. 2002. Characterization of mice deficient in the Src family nonreceptor tyrosine kinase Frk/rak. Mol Cell Biol 22:5235-5247.
8. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Chuang YY, Chen Y, Gadisetti, Chandramouli VR, Cook JA, Coffin D, Tsai MH, de Longueville F, Bertholet V, Remacle J. 2004. DNA microarrays as a tool in toxicogenomics. Comb Chem High Throughput Screen 7:207-211.
9. DeGraff W, Yan H, Zhao S, Russo A, Liu ET, Mitchell JB. 2002. Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res 62:6246-6254.
10. Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R, Furth P, Hunter K, Kucherlapati R, Simon R, Liu ET, Green JE. 2002. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA 99:6967-6972.
11. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. 2001. Delineation of prognostic biomarkers in prostate cancer. Nature 412:822-826.
12. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, Behm FG, Pui CH, Downing JR, Gilliland DG, Lander ES, Golub TR, Look AT. 2002. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1:75-87.
13. Garber K. 2004. Gene expression tests foretell breast cancer's future. Science 303:1754-1755.
14. Guo QM, Malek RL, Kim S, Chiao C, He M, Ruffy M, Sanka K, Lee NH, Dang CV, Liu ET. 2000. Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res 60:5922-5928.
15. Harrington CA, Rosenow C, Retief T. 2000. Monitoring gene expression using DNA microarrays. Curr Opin Microbiol 3:285-291.
16. Heinloth AN, Irwin RD, Boorman GA, Nettesheim P, Fannin RD, Sieber SO, Snell ML, Tucker CJ, Li L, Travlos GS, Vansant G, Blackshear PE, Tennant RW, Cunningham ML, Paules RS. 2004. Gene expression profiling of rat livers reveals indicators of potential adverse effects. Toxicol Sci 80:193-202.
17. Hood E. 2004. Taking stock of toxicogenomics: mini-monograph offers overview. Environ Health Perspect 112:A231.
18. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai H, He YD, Kidd MJ, King AM, Meyer MR, Slade D, Lum PY, Stepaniants SB, Shoemaker DD, Gachotte D, Chakraburtty K, Simon J, Bard M, Friend SH. 2000. Functional discovery via a compendium of expression profiles. Cell 102:109-126.
19. Hunter KW. 2003. Allelic diversity in the host genetic background may be an important determinant in tumor metastatic dissemination. Cancer Lett 200:97-105.
20. Iritani BM, Eisenman RN. 1999. c-Myc enhances protein synthesis and cell size during B lymphocyte development. Proc Natl Acad Sci USA 96:13180-13185.
21. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. 2000. Molecular portraits of human breast tumours. Nature 406:747-752.
22. Kapranov P, Cawley SE, Drenkow J, Bekiranov S, Strausberg RL, Fodor SP, Gingeras TR. 2002. Large-scale transcriptional activity in chromosomes 21 and 22. Science 296:916-919.
23. Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH, Liu ET, Yu Q. 2004. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem 279:21183-21192.
24. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, Imai K, Nakamura Y. 2003. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22:2192-2205.
25. Kramer JA, Pettit SD, Amin RP, Bertram TA, Car B, Cunningham M, Curtiss SW, Davis JW, Kind C, Lawton M, Naciff JM, Oreffo V, Roman RJ, Sistare FD, Stevens J, Thompson K, Vickers AE, Wild S, Afshari CA. 2004. Overview on the application of transcription profiling using selected nephrotoxicants for toxicology assessment. Environ Health Perspect 112:460-464.
26. Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES, Golub TR. 2001. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98:10787-10792.
27. Lee TI, Rinaldi NJ, Robert F, Odom DT, Bar-Joseph Z, Gerber GK, Hannett NM, Harbison CT, Thompson CM, Simon I, Zeitlinger J, Jennings EG, Murray HL, Gordon DB, Ren B, Wyrick JJ, Tagne JB, Volkert TL, Fraenkel E, Gifford DK, Young RA. 2002. Transcriptional regulatory networks in Saccharomyces cerevisiae. Science 298:799-804.
28. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Marton MJ, DeRisi JL, Bennett HA, Iyer VR, Meyer MR, Roberts CJ, Stoughton R, Burchard J, Slade D, Dai H, Bassett DE Jr, Hartwell LH, Brown PO, Friend SH. 1998. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med 4:1293-1301.
29. McConnell MJ, Chevallier N, Berkofsky-Fessler W, Giltnane JM, Malani RB, Staudt LM, Licht JD. 2003. Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol 23:9375-9388.
30. Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR. 2002. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68-74.
31. Miller LD, Park KS, Guo QM, Alkharouf NW, Malek RL, Lee NH, Liu ET, Cheng SY. 2001. Silencing of Wnt signaling and activation of multiple metabolic pathways in response to thyroid hormone-stimulated cell proliferation. Mol Cell Biol 21:6626-6639.
32. Miller LD, Long PM, Wong L, Mukherjee S, McShane LM, Liu ET. 2002. Optimal gene expression analysis by microarrays. Cancer Cell 2:353-361.
33. Miller LD, McPhie P, Suzuki H, Kato Y, Liu ET, Cheng SY. 2004. Multi-tissue gene expression analysis in a mouse model of thyroid hormone resistance. Genome Biol 5:R31.
34. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC. 2003. PGC-1 alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267-273.
35. Norman TC, Smith DL, Sorger PK, Drees BL, O'Rourke SM, Hughes TR, Roberts CJ, Friend SH, Fields S, Murray AW. 1999. Genetic selection of peptide inhibitors of biological pathways. Science 285:591-595.
36. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack R, Schadt EE, Stoughton R, Shoemaker DD. 2003. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302:2141-2144.
37. Qiu, et al. Cancer, In press.
38. Roberts CJ, Nelson B, Marton MJ, Stoughton R, Meyer MR, Bennett HA, He YD, Dai H, Walker WL, Hughes TR, Tyers M, Boone C, Friend SH. 2000. Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles. Science 287:873-880.
39. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, et al. 2002. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947.
40. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO. 2000. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227-235.
41. Ruan Y, Le Ber P, Ng HH, Liu ET. 2004. Interrogating the transcriptome. Trends Biotechnol 22:23-30.
42. Sawyers CL. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39.
43. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN. 2000. A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236-244.
44. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. 2002. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1:203-209.
45. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423.
46. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. 2003. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393-10398.
47. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, et al. 2002. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4:R3.
48. Staudt LM. 2002. It's ALL in the diagnosis. Cancer Cell 1:109-110.
49. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES, Golub TR. 2001. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98:10787-10792.
50. Teicher BA, Alvarez E, Menon K, Esterman MA, Considine E, Shih C, Faul MM. 2002a. Antiangiogenic effects of a protein kinase C beta-selective small molecule. Cancer Chemother Pharmacol 49:69-77.
51. Teicher BA, Menon K, Alvarez E, Shih C, Faul MM. 2002b. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts. Invest New Drugs 20:241-251.
52. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B, Delwel R. 2004. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350:1617-1628.
53. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, et al. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009.
54. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536.
55. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. 2002. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624-629.
56. Wei CL, Ng P, Chiu KP, Wong CH, Ang CC, Lipovich L, Liu ET, Ruan Y. 2004. 5′ Long serial analysis of gene expression (LongSAGE) and 3′ Long SAGE for transcriptome characterization and genome annotation. Proc Natl Acad Sci USA 2004 Jul 22 [Epub ahead of print].
57. Wheeler GD. 2003. Ruboxistaurin (Eli Lilly). IDrugs 6:159-163.
58. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, et al. 2002. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133-143.